Biography

• Dr. Jun Li, male, was born in August 1980. In June 2002, he graduated from the University of Science and Technology of China (USTC) with a Bachelor of Science Degree in cell biology. In September of the same year, he studied in molecular immunology of USTC as an exam free student and obtained a master's degree. In April 2006, he went to Japan to study in the Department of human architecture, Tokyo Medical University. In March 2011, he received his doctorate.

• At present, he is the youth project leader and associate researcher of "State Key Laboratory of Oncogenes and Related Genes" of Shanghai Cancer Institute, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University (SJTU). In recent years, he has devoted himself to the study of neuroendocrine regulation of tumor microenvironment, and achieved a series of important research results. He has published 41 SCI papers, including 6 papers of first / co-first author, 8 papers of corresponding authors, 1 paper with impact factor > 20, 5 paper with impact factor > 10, 3 papers with impact factor > 5, mainly including: Journal of Hepatology，Gastroenterology，EBioMedicine，Int J Biol Sci，Oncogene，FASEB J and other international journals. He participated in the translation of one book "tumor microenvironment". Three national invention patents were applied and two patents were authorized.

• He has presided 2 General programs of National Natural Science Foundation of China (NSFC), 1 Youth program of NSFC, 1 Shanghai Natural Science Foundation, 1 major special sub project of the 12th Five Year Plan as the main technical backbone, 1 Academician foundation of Shanghai Cancer Institute, 2 Shuobo innovation fund of Shanghai Cancer Institute, participated in 1 General and 3 Youth programs of NSFC. As the second adult, he got the second prize of Shanghai Medical Science and Technology Award. In 2019, he was selected into the "peak plateau" double hundred person plan of School of Medicine, SJTU.

Publications

1. Li J#, Yang XM#, Wang YH#, Feng MX, Liu XJ, Zhang YL, Huang S, Wu Z, Xue F, Qin WX, Gu JR, Xia Q*, Zhang ZG*. Monoamine oxidase A suppresses hepatocellular carcinoma metastasis by inhibiting the adrenergic system and its transactivation of EGFR signaling. J Hepatol. 2014; 60(6): 1225-1234. (IF=18.946)

2. Li J#, Wang Y#, Ma M#, Jiang S#, Zhang X, Zhang Y, Yang X, Xu C, Tian G, Li Q, Wang Y, Zhu L, Nie H, Feng M, Xia Q, Gu J, Xu Q*, Zhang Z*. Autocrine CTHRC1 activates hepatic stellate cells and promotes liver fibrosis by activating TGF-β signaling. EBioMedicine. 2019; 40: 43-55. (IF=11.205)

3. Li J#, Xu CJ#, Tian GA#, Li Q#, Li DX#, Yan F, Zhou YQ, Huang PQ, Xie JX, Wang X, Jiang SH, Wang YH, Song J, Zhang XL, Yi SQ, Hu LP*, Xu Q*, Li XW*, Zhang ZG*. Spatiotemporal quantification of metastatic tumour cell growth and distribution in lymph nodes by whole-mount tissue 3D imaging. Int J Biol Sci. 2022; 18(10): 3993-4005. (IF=10.750)

4. Jiang SH#, Li J#, Dong FY#, Yang JY, Liu DJ, Yang XM, Wang YH, Yang MW, Fu XL, Zhang XX, Li Q, Pang XF, Huo YM, Li J, Zhang JF, Lee HY, Lee SJ, Qin WX, Gu JR, Sun YW*, Zhang ZG*. Increased Serotonin Signaling Contributes to the Warburg Effect in Pancreatic Tumor Cells under Metabolic Stress and Promotes Growth of Pancreatic Tumors in Mice. Gastroenterology. 2017; 153(1): 277-291. (IF=20.773)

5. Shen Y#, Zhao S#, Wang S, Pan X, Zhang Y, Xu J, Jiang Y, Li H, Zhang Q, Gao J, Yang Q, Zhou Y, Jiang S, Yang H, Zhang Z, Zhang R, Li J*, Zhou D*. S1P/S1PR3 axis promotes aerobic glycolysis by YAP/c-MYC/PGAM1 axis in osteosarcoma. EBioMedicine. 2019; 40: 210-223. (IF=11.205)

6. Zhang XL#, Hu LP#, Yang Q#, Qin WT, Wang X, Xu CJ, Tian GA, Yang XM, Yao LL, Zhu L, Nie HZ, Li Q,   Xu Q, Zhang ZG, Zhang YL*, Li J*, Wang YH*, Jiang SH*. CTHRC1 promotes liver metastasis by reshaping infiltrated macrophages through physical interactions with TGF-b receptors in colorectal cancer. Oncogene. 2021; 40: 3959-3973. (IF=9.867)

7. Hu LP#, Huang W#, Wang X#, Xu C#, Qin WT, Li D, Tian G, Li Q, Zhou Y, Chen S, Nie HZ, Hao Y, Song J, Zhang XL, Sundquist J, Sundquist K, Li J*, Jiang SH*, Zhang ZG*, Ji JG*. Terbinafine prevents colorectal cancer growth by inducing dNTP starvation and reducing immune suppression. Mol Ther. 2022; S1525-0016(22)00375-6. (IF=12.910) doi: 10.1016/j.ymthe.2022.06.015.

8. Jiang SH#, Dong FY, Da LT, Yang XM, Wang XX, Weng JY, Feng L, Zhu LL, Zhang YL, Zhang ZG, Sun YW, Li J*, Xu MJ*. Ikarugamycin inhibits pancreatic cancer cell glycolysis by targeting hexokinase 2. FASEB J. 2020; 34(3): 3943-3955. (IF=5.391)

9. Wang YH#, Huang S#, Zhu L#, Yang Q, Yang XM, Gu JR, Zhang ZG, Nie HZ*, Li J*. Alternative transcription start site selection in ACSS2 controls its nuclear localization and promotes ribosome biosynthesis in hepatocellular carcinoma. Biochem Biophys Res Commun. 2019; 514(3): 632-638. (IF=2.705)

10. Zhu L#, Tian GA#, Yang Q, De GJ, Zhang ZG, Wang YH, Nie HZ, Zhang YL, Yang XM*, Li J*. Thyroid hormone receptor beta1 suppresses proliferation and migration by inhibiting PI3K/AKT signaling in human colorectal cancer cells. Oncol Rep. 2016; 36(3):1419-1426. (IF=2.976)

11. Zhang YL#, Xing X#, Cai LB, Zhu L, Yang XM, Wang YH, Yang Q, Nie HZ, Zhang ZG, Li J*, Zhang XL*. Integrin α9 Suppresses Hepatocellular Carcinoma Metastasis by Rho GTPase Signaling. J Immunol Res. 2018; 2018: 4602570. (IF=3.298)

12. Yang XM#, You HY#, Li Q, Ma H, Wang YH, Zhang YL, Zhu L, Nie HZ, Qin WX, Zhang ZG, Li J*. CTHRC1 promotes human colorectal cancer cell proliferation and invasiveness by activating Wnt/PCP signaling. Int J Clin Exp Pathol. 2015; 8(10): 12793-12801. (IF=1.706)

13. Wang YH#, Li J#, Wen SY#, Yang XM, Zhang YL, Wang ZJ*, Zhang ZG*. CHRM3 is a novel prognostic factor of poor prognosis in patients with endometrial carcinoma. Am J Transl Res. 2015; 7(5): 902-911. (IF=2.829)

14. Jiang SH#, Wang Y#, Yang JY#, Li J#, Feng MX, Wang YH, Yang XM, He P, Tian GA, Zhang XX, Li Q, Cao XY, Huo YM, Yang MW, Fu XL, Li J, Liu DJ, Dai M, Wen SY, Gu JR, Hong J, Hua R, Zhang ZG*, Sun YW*. Overexpressed EDIL3 predicts poor prognosis and promotes anchorage-independent tumor growth in human pancreatic cancer. Oncotarget. 2016; 7(4): 4226-4240. (IF=5.168)

15. Nie H#, Li J, Yang XM, Cao QZ, Feng MX, Xue F, Wei L, Qin W, Gu J, Xia Q*, Zhang ZG*. Mineralocorticoid receptor suppresses cancer progression and Warburg effect by modulating miR-338-3p-PKLRaxis in hepatocellular carcinoma. Hepatology. 2015; 62(4): 1145-1159. (IF=13.246)

16. Yang XM#, Cao XY#, He P#, Li J, Feng MX, Zhang YL, Zhang XL, Wang YH, Yang Q, Zhu L, Nie HZ, Jiang SH, Tian GA, Zhang XX, Liu Q, Ji J, Zhu X, Xia Q*, Zhang ZG*. Overexpression of Rac GTPase Activating Protein 1 Contributes to Proliferation of Cancer Cells by Reducing Hippo Signaling to Promote Cytokinesis. Gastroenterology. 2018; 155(4): 1233-1249. (IF=20.773)

17. Zhang YL#, Li Q#, Yang XM#, Fang F, Li J, Wang YH, Yang Q, Zhu L, Nie HZ, Zhang XL, Feng MX, Jiang SH, Tian GA, Hu LP, Lee HY, Lee SJ, Xia Q, Zhang ZG*. SPON2 Promotes M1-like Macrophage Recruitment and Inhibits Hepatocellular Carcinoma Metastasis by Distinct Integrin-Rho GTPase-Hippo Pathways. Cancer Res. 2018; 78(9): 2305-2317. (IF=9.13)